Market Cap | 7.37M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -19.52M | Forward P/E | -0.34 | EPS next Y | - | 50D Avg Chg | 8.00% |
Sales | 7.47k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -41.00% |
Dividend | N/A | Price/Book | 0.85 | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | 2.00 | Quick Ratio | 0.98 | Shares Outstanding | 8.66M | 52W Low Chg | 40.00% |
Insider Own | 12.02% | ROA | -219.89% | Shares Float | 4.72M | Beta | 0.48 |
Inst Own | 14.01% | ROE | -454.72% | Shares Shorted/Prior | 174.44K/701.41K | Price | 3.64 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 11,241 | Target Price | - |
Oper. Margin | -263,285.18% | Earnings Date | Nov 7 | Volume | 8,775 | Change | -3.70% |
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Telling Fred | Director Director | Nov 30 | Sell | 3.5681 | 3,500 | 12,488 | 38,345 | 12/01/23 |
Telling Fred | Director Director | Jun 17 | Buy | .2860 | 10,084 | 2,884 | 1,010,000 | 06/21/22 |
Sullivan Michael O'Keefe | Interim PEO, CFO Interim PEO, CFO | Mar 29 | Buy | .3461 | 20,000 | 6,922 | 34,255 | 03/30/22 |